Search results
Results from the WOW.Com Content Network
Ranitidine, previously sold under the brand name Zantac [a] among others, is a medication used to decrease stomach acid production. [12] It was commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [12] It can be given by mouth, injection into a muscle, or injection into a vein.
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
A separate list for children up to 12 years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007 and is in its 9th edition. [ 10 ] [ 21 ] [ 22 ] [ 23 ] It was created to make sure that the needs of children were systematically considered such as availability of proper formulations .
Before starting therapy, the possibility of gastric ulcer malignancy is excluded, since ranitidine bismuth citrate can mask the symptoms of carcinoma of the stomach. Patients with mild or moderate renal impairment with CC of at least 50 ml / min do not require dose adjustment. In elderly patients with CC more than 25 ml / min, the dose is not ...
This ruling has removed the requirement of stating pregnancy categories in prescription drug labels. [99] Australia's categorization system takes into account birth defects, the effects around birth or when the mother gives birth, and problems that will arise later in the child's life due to the drug taken. The system places them into a ...
The pregnancy category of a medication is an assessment of the risk of fetal injury due to the pharmaceutical, if it is used as directed by the mother during pregnancy. It does not include any risks conferred by pharmaceutical agents or their metabolites in breast milk. Every drug has specific information listed in its product literature.
Nizatidine was developed by Eli Lilly, and was first marketed in 1988. [3] It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine.
[24] [25] [26] Use of this drug is not recommended for people with chronic kidney failure, as it might cause aluminium accumulation and toxicity. A few well-controlled studies have been carried out investigating the safety and efficacy of sucralfate in children and pregnant women (Pregnancy Category B). [1] [27] [28]